RNA Therapeutics & Manufacturing Asia 2025
Nucleic Acid Insights 2025; 2(8), 159–160
DOI: 10.18609/nuc.2025.021
As part of our ongoing coverage of major gatherings in the advanced therapeutics space, Nucleic Acid Insights presents a preview of RNA Therapeutics & Manufacturing Asia 2025. Scheduled for November 5–6, 2025 at the Amari Bangkok, Thailand, this conference will spotlight advanced RNA drug development, scalable manufacturing, and innovative delivery technologies. In this preview, we highlight key sessions, speakers, and themes that will shape the conversation at one of Asia-Pacific’s most anticipated nucleic acid events.
Advancing RNA innovation through collaboration and novel clinical strategies
A variety of leading experts will explore the evolving landscape of RNA-based therapies, diagnostics, and public health strategies. Felicia Pradera (Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna) will explore how regional partnerships and translational research are accelerating RNA innovation across the Asia-Pacific. Additionally, Subhash Thuluva (Senior VP & Head-Clinical Development, Biological E. Limited) will present a comprehensive roadmap for RNA vaccine development, focusing on how adaptive trial designs and accelerated pathways will shape future clinical strategies. He will explain how developers can select endpoints, assess immunogenicity, and implement safety monitoring. The session will also highlight how teams can prepare for regulatory review and mitigate risks as RNA vaccine candidates move toward approval.
Breakthroughs in RNA delivery technologies
The event will also showcase next-generation RNA delivery technologies poised to transform therapeutic development. Ying Bo (CEO, Abogen Biosciences, China) will introduce Abogen’s advanced RNA platform and next-gen lipid nanoparticles (LNPs), which will enable safe and effective mRNA delivery in preclinical models. He will also share clinical updates on how these innovations will support vaccines and treatments for cancer and autoimmune diseases. Poon Hung Fai (CEO, Sirnaomics) will present Sirnaomics’ proprietary siRNA delivery systems—PNP and GalNAc—that will help to enable precise targeting for conditions like cancer and fibrosis. He will highlight promising clinical data from trials STP705 and STP122G and reveal how novel approaches such as AODC will expand RNAi therapies to the CNS, lung, and gut. Together, these leaders will outline how RNA delivery breakthroughs will drive the next wave of precision medicine.
Advanced RNA modalities for next-gen cancer immunotherapy
The conference will also highlight advancements, challenges, and recent breakthroughs in novel RNA modalities. Wonil Kim (Chief Scientific Officer, Aston Sci.) will introduce Th-Vac®, an AI-powered platform for designing mRNA cancer vaccines that target antigens like TROP2, PD-L1, IDO, and KRAS to activate CD4+ T cells. The approach aims to overcome limitations in current immunotherapies.
The RNA Therapeutics & Manufacturing Asia 2025 conference promises to be a landmark gathering spotlighting the latest innovations in RNA-based drug development, scalable production, and delivery technologies across the Southeast Asia region. Uniting leading scientists, biotech executives, and regulators, the event will delve into strategies for overcoming manufacturing bottlenecks, advancing next-gen RNA platforms, and accelerating clinical translation. Key sessions will feature breakthroughs in mRNA and siRNA therapeutics, precision delivery systems, and CRISPR-RNA integration, offering a comprehensive view into the future of RNA medicines and personalized healthcare in the region.
As a reader of Nucleic Acid Insights, you’re entitled to a 15% discount on delegate tickets—just use the code RNAxBioinsights15! You can find out more about the RNA Therapeutics & Manufacturing Asia 2025 event here.
Want to keep up to date with all of the latest nucleic acid events you might want to attend or exhibit at? Explore our free online Events Calendar here.